Inhibikase Therapeutics (IKT) Non Operating Investment Income (2022 - 2026)
Inhibikase Therapeutics' (IKT) quarterly Non Operating Investment Income came in at -$48095.0 in Q1 2026, down 232.56% year-on-year from $36281.0 in Q1 2025, and down 285.04% on a QoQ basis from $25991.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Non Operating Investment Income (2022 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 5 years of Non Operating Investment Income data on file, last reported at -$48095.0 in Q1 2026.
- On a quarterly basis, Non Operating Investment Income fell 232.56% year-over-year to -$48095.0 in Q1 2026; TTM through Mar 2026 was -$25326.0, a 3140.34% decrease from a year earlier, with the FY2025 full-year figure at $59050.0, up 254.89% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at -$48095.0, down from $25991.0 in the prior quarter.
- Over the last five years, Non Operating Investment Income for IKT reached as high as $36281.0 in Q1 2025 and fell as low as -$167536.0 in Q2 2023.
- Historically, Non Operating Investment Income has averaged -$13858.9 across 5 years, with a median of -$234.5 in 2024.
- On a YoY basis, Non Operating Investment Income climbed as much as 1455.29% in 2025 and fell as far as 354.77% in 2025.
- Year by year, Non Operating Investment Income stood at $26828.0 in 2022, then tumbled by 94.14% to $1571.0 in 2023, then tumbled by 2582.62% to -$39002.0 in 2024, then surged by 166.64% to $25991.0 in 2025, then slumped by 285.04% to -$48095.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Investment Income figures were -$48095.0 in Q1 2026, $25991.0 in Q4 2025, and -$1245.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - | -48,095.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48,095.00 |
| Mar 31, 2026 | -48,095.00 |
| Dec 31, 2025 | 25,991.00 |
| Dec 31, 2025 | 25,991.00 |
| Sep 30, 2025 | -1,245.00 |
| Sep 30, 2025 | -1,245.00 |
| Jun 30, 2025 | -1,977.00 |
| Jun 30, 2025 | -1,977.00 |
| Mar 31, 2025 | 36,281.00 |
| Mar 31, 2025 | 36,281.00 |
| Dec 31, 2024 | -39,002.00 |
| Dec 31, 2024 | -39,002.00 |
| Sep 30, 2024 | 2,778.00 |
| Sep 30, 2024 | 2,778.00 |
| Jun 30, 2024 | 776.00 |
| Jun 30, 2024 | 776.00 |
| Mar 31, 2024 | -2,677.00 |
| Mar 31, 2024 | -2,677.00 |
| Sep 30, 2023 | 1,571.00 |
| Sep 30, 2023 | 1,571.00 |